What's in a Perspective?
Jan 1, 2010, 00:00 AM
10.1111/j.1524-4733.2009.00674.x
https://www.valueinhealthjournal.com/article/S1098-3015(10)60385-3/fulltext
Section Title :
Section Order :
26
First Page :
The history of pharmaceutical costing for use in costeffectiveness studies has been marked more by convenience— what pricing data are readily available?—than by science—what
opportunities are forgone when we use a particular drug? For too long, our field has relied on average wholesale price, when there is substantial evidence that it is an inappropriate measure [1,2]. Thus, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force on Good Research Practices—Use of Drug Costs for Cost Effectiveness Analysis reports on drug costing [3–8] is commendable.
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)60385-3&doi=10.1111/j.1524-4733.2009.00674.x
HEOR Topics :
- Best Research Practices
- Cost-comparison, Effectiveness, Utility, Benefit Analysis
- Economic Evaluation
- Health Policy & Regulatory
- Organizational Practices
- Pricing Policy & Schemes